Intrust Bank NA Purchases 2,685 Shares of Novo Nordisk A/S (NYSE:NVO)

Intrust Bank NA grew its position in Novo Nordisk A/S (NYSE:NVO) by 57.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 7,394 shares of the company’s stock after buying an additional 2,685 shares during the period. Intrust Bank NA’s holdings in Novo Nordisk A/S were worth $765,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Eagle Ridge Investment Management lifted its position in Novo Nordisk A/S by 17.8% in the 4th quarter. Eagle Ridge Investment Management now owns 3,712 shares of the company’s stock valued at $384,000 after acquiring an additional 562 shares in the last quarter. Naviter Wealth LLC raised its stake in shares of Novo Nordisk A/S by 19.1% in the fourth quarter. Naviter Wealth LLC now owns 49,304 shares of the company’s stock worth $5,100,000 after purchasing an additional 7,914 shares during the last quarter. Choreo LLC lifted its holdings in shares of Novo Nordisk A/S by 6.7% during the fourth quarter. Choreo LLC now owns 3,108 shares of the company’s stock valued at $322,000 after purchasing an additional 194 shares in the last quarter. Intellectus Partners LLC boosted its position in shares of Novo Nordisk A/S by 11.4% during the fourth quarter. Intellectus Partners LLC now owns 8,270 shares of the company’s stock valued at $856,000 after buying an additional 848 shares during the last quarter. Finally, Stonebrook Private Inc. bought a new stake in Novo Nordisk A/S in the 4th quarter worth about $235,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 1.1 %

Shares of NYSE:NVO opened at $128.28 on Wednesday. The stock has a 50 day moving average of $127.05 and a 200 day moving average of $112.58. The company has a market cap of $575.66 billion, a PE ratio of 47.42, a price-to-earnings-growth ratio of 2.12 and a beta of 0.41. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.05. The business had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.32 EPS for the current year.

Wall Street Analyst Weigh In

NVO has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price for the company. UBS Group initiated coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating on the stock. Finally, BMO Capital Markets initiated coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.